The abstract is read at the publisher; the summary is JClub's.
SABR is linked to higher 3-year all-cause mortality than surgical resection in eligible early-stage NSCLC patients, with 30.3% vs 21.6% mortality.
- Why it matters: Randomized trials have struggled to recruit and may not match real-world eligibility, leaving uncertainty about whether SABR can replace surgery for early-stage non-small cell lung cancer.
- What they did: Using England’s National Cancer Registry (2015–2020), the study emulated a target trial in 12,546 T1-2N0M0 patients receiving SABR or surgery within 6 months, using instrumental variable analysis to reduce confounding.
- The result: Adjusted 3-year all-cause mortality was 30.3% for SABR and 21.6% for surgery (mean absolute risk difference 8.8 pp; 95% CI 1.4 to 16.2; P=.02), with lung cancer-specific mortality 20.6% vs 14.5% (P=.07).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.